Advertisement

Topics

Human Laboratory Study of Smokeless Tobacco Products

2014-07-24 14:06:37 | BioPortfolio

Summary

With the advent of restrictions on public smoking, the tobacco industry has introduced a variety of novel smokeless tobacco products (NSTP) to allow continued tobacco use. These products typically have lower tobacco-specific nitrosamines, carcinogens and nicotine than conventional smokeless products out on the market. No studies have compared the effects of NSTP and medicinal nicotine products (MNP) in smokeless tobacco users and whether some of the NSTP products may serve as a cessation tool for smokeless tobacco users. Our hypothesis is that the effects from these products will be directly related to their nicotine content and sensory effects. Products that produce greater effects on outcome measures may serve as potential cessation tools.

Description

Treatment will be a 3-period crossover study using Commit Nicotine Lozenge, Stonewall Disposable Tobacco Pieces and Camel Snus Frost Pouches. Each period will last 14 days with 11 days of product use and 1.5 days abstinence of all nicotine-containing products for a total of 10 weeks. Participants will begin the study by completing a baseline assessment on their own product, Skoal Wintergreen.

Study Design

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label

Conditions

Smokeless Tobacco

Intervention

Nicotine Lozenge, Stonewall Dissolvable Tobacco Pieces, Camel Snus Frost, Skoal Wintergreen

Location

Tobacco Research Center
Minneapolis
Minnesota
United States
55455

Status

Recruiting

Source

Masonic Cancer Center, University of Minnesota

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-07-24T14:06:37-0400

Clinical Trials [661 Associated Clinical Trials listed on BioPortfolio]

Smoking Cessation Medications: Efficacy, Mechanisms and Algorithms

The proposed work will advance the understanding and effectiveness of tobacco dependence treatment and result in more smokers quitting successfully.

Single-Dose Bioequivalence Study Comparing Two 4 mg Nicotine Lozenges

The purpose of the study is to compare the pharmacokinetic (PK) profiles and assess bioequivalence between a new nicotine lozenge and a reference nicotine lozenge in healthy smokers

Single-Dose Bioequivalence Study Comparing Two 2 mg Nicotine Lozenges

The purpose of the study is to compare the pharmacokinetic (PK) profiles and assess bioequivalence between a new nicotine lozenge and a reference nicotine lozenge in healthy smokers.

Early Effects of a New Oral Nicotine Replacement Product and NiQuitin™ Lozenge

A comparison of two products for oral nicotine replacement with respect to relief of urges to smoke after single doses of nicotine.

Smoking Cessation Intervention: Effectiveness in Primary Care

The information gathered in this study may help to develop more effective ways to help people quit smoking and stay quit in the future.

PubMed Articles [1146 Associated PubMed Articles listed on BioPortfolio]

Randomized Trial to Compare Smoking Cessation Rates of Snus, with and without Smokeless Tobacco Health-Related Information, and a Nicotine Lozenge.

Nicotine replacement medications are moderately effective in increasing quit rates. However, some smokers reject such aids, suggesting the value of considering alternative options. Snus, a smokeless t...

Healthcare Utilization and Expenditures Attributable to Smokeless Tobacco Use among US Adults.

This study estimated the healthcare utilization and expenditures attributable to the use of smokeless tobacco (ST) which includes chewing tobacco, snuff, dip, snus, and dissolvable tobacco among US ad...

Consortium on Methods Evaluating Tobacco: Research Tools to Inform FDA Regulation of Snus.

The U.S. Food and Drug Administration (FDA) has purview over tobacco products. To set policy, the FDA must rely on sound science, yet most existing tobacco research methods have not been designed to s...

Snus and snuff use in Switzerland among young men: are there beneficial effects on smoking?

There are few recent longitudinal studies on smokeless tobacco products (SLT) and smoking outside the United States or European Nordic countries. The present longitudinal study tests whether Swedish t...

The Effects of Nicotine and Tobacco use on Brain Reward Function: Interaction with Nicotine Dependence Severity.

This study investigated the effects of nicotine/tobacco on neural activation during performance of a monetary incentivized delay task.

Medical and Biotech [MESH] Definitions

Nicotine is highly toxic alkaloid. It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimulates neurons and ultimately blocks synaptic transmission. Nicotine is also important medically because of its presence in tobacco smoke.

A plant genus of the family SOLANACEAE. Members contain NICOTINE and other biologically active chemicals; its dried leaves are used for SMOKING.

The N-glucuronide conjugate of cotinine is a major urinary metabolite of NICOTINE. It thus serves as a biomarker of exposure to tobacco SMOKING. It has CNS stimulating properties.

Tobacco used to the detriment of a person's health or social functioning. Tobacco dependence is included.

The aggregate business enterprise of agriculture, manufacture, and distribution related to tobacco and tobacco-derived products.

More From BioPortfolio on "Human Laboratory Study of Smokeless Tobacco Products"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...


Searches Linking to this Trial